Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin M Ellingson

Showing results (201-210 of 286) with videos related to

Pageof 29
Sort By:
Biorxiv : the Preprint Server for Biology|August 6, 2025
GFAP Degradation in TBI: Linking Novel Modified Products to Astrocyte Pathology and Patient OutcomeIna-Beate Wanner, Julia Halford, Jonathan Lopez, et al.
Scientific Reports|July 23, 2021
Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imagingHamed Akbari, Anahita Fathi Kazerooni, Jeffrey B Ware, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
Neuro-Oncology Advances|May 12, 2026
A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational statusChuyin Yang, Ryan Mostafavi, Collin Le, et al.
Neuro-Oncology|August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapyHuyTram N Nguyen, Amy Lie, Tie Li, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Neuro-Oncology Advances|March 7, 2025
A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastomaBenjamin M Ellingson, Qunicy Okobi, Robert Chong, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Neuro-Oncology|September 1, 2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically-confirmed malignant transformation in IDH-mutant gliomasNicholas S Cho, Viên Lam Le, Ashley Teraishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Pageof 29

Showing results (201-210 of 286) with videos related to

Sort By:
Pageof 29
Biorxiv : the Preprint Server for Biology|August 6, 2025
GFAP Degradation in TBI: Linking Novel Modified Products to Astrocyte Pathology and Patient OutcomeIna-Beate Wanner, Julia Halford, Jonathan Lopez, et al.
Scientific Reports|July 23, 2021
Quantification of tumor microenvironment acidity in glioblastoma using principal component analysis of dynamic susceptibility contrast enhanced MR imagingHamed Akbari, Anahita Fathi Kazerooni, Jeffrey B Ware, et al.
Neuro-Oncology|December 18, 2019
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)Timothy F Cloughesy, Andrew Brenner, John F de Groot, et al.
Neuro-Oncology Advances|May 12, 2026
A single-institution retrospective study of multicentric gliomas stratified by <i>IDH</i> mutational statusChuyin Yang, Ryan Mostafavi, Collin Le, et al.
Neuro-Oncology|August 31, 2016
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapyHuyTram N Nguyen, Amy Lie, Tie Li, et al.
Neuro-Oncology|May 9, 2019
Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRIJingwen Yao, Ararat Chakhoyan, David A Nathanson, et al.
Neuro-Oncology Advances|March 7, 2025
A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastomaBenjamin M Ellingson, Qunicy Okobi, Robert Chong, et al.
Neuro-Oncology|October 11, 2017
Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglioMartha Nowosielski, Benjamin M Ellingson, Olivier L Chinot, et al.
Neuro-Oncology|September 1, 2025
Perfusion, diffusion, and anatomical MRI characteristics of pathologically-confirmed malignant transformation in IDH-mutant gliomasNicholas S Cho, Viên Lam Le, Ashley Teraishi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 23, 2015
The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with BevacizumabRaymond Y Huang, Rifaquat Rahman, Karla V Ballman, et al.
Pageof 29